Last reviewed · How we verify
Lozol (INDAPAMIDE)
Lozol (Indapamide) is a thiazide-like diuretic medication originally developed by Sanofi Aventis Us. It targets carbonic anhydrase 7 and is used to treat edema and hypertensive disorders. Lozol is a small molecule modality with 90% bioavailability and was FDA approved in 1983. The medication is now off-patent with multiple generic manufacturers. As a diuretic, Lozol works by increasing urine production to reduce fluid buildup in the body.
At a glance
| Generic name | INDAPAMIDE |
|---|---|
| Sponsor | Sanofi Aventis Us |
| Drug class | Thiazide-like Diuretic [EPC] |
| Target | Carbonic anhydrase 7 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1983 |
Approved indications
- Edema
- Hypertensive disorder
Common side effects
- Hypokalemia
- Headache
- Constipation
- Nausea
- Diarrhea
- Dizziness
- Lightheadedness
- Drowsiness
- Fatigue
- Vertigo
- Insomnia
- Muscle cramps
Drug interactions
- lithium
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions (PHASE1)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs (PHASE4)
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Antihypertensive Drug Selection Based on Hemodynamic Phenotypes (PHASE4)
- Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension (PHASE3)
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lozol CI brief — competitive landscape report
- Lozol updates RSS · CI watch RSS